These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35970014)

  • 21. Knowledge base toward understanding actionable alterations and realizing precision oncology.
    Takeuchi S; Okuda S
    Int J Clin Oncol; 2019 Feb; 24(2):123-130. PubMed ID: 30542800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
    Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
    Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer.
    Keller RB; Mazor T; Sholl L; Aguirre AJ; Singh H; Sethi N; Bass A; Nagaraja AK; Brais LK; Hill E; Hennessey C; Cusick M; Del Vecchio Fitz C; Zwiesler Z; Siegel E; Ovalle A; Trukhanov P; Hansel J; Shapiro GI; Abrams TA; Biller LH; Chan JA; Cleary JM; Corsello SM; Enzinger AC; Enzinger PC; Mayer RJ; McCleary NJ; Meyerhardt JA; Ng K; Patel AK; Perez KJ; Rahma OE; Rubinson DA; Wisch JS; Yurgelun MB; Hassett MJ; MacConaill L; Schrag D; Cerami E; Wolpin BM; Nowak JA; Giannakis M
    JCO Precis Oncol; 2023 Jan; 7():e2200342. PubMed ID: 36634297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The molecular tumor board: a tool for the governance of precision oncology in the real world.
    Incorvaia L; Russo A; Cinieri S
    Tumori; 2022 Aug; 108(4):288-290. PubMed ID: 34918610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current Status and Prospects of the Comprehensive Cancer Genome Profiling].
    Imoto I; Fukue M; Takaiso N
    Gan To Kagaku Ryoho; 2021 Jan; 48(1):7-11. PubMed ID: 33468714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
    Hayashi H; Tanishima S; Fujii K; Mori R; Okada C; Yanagita E; Shibata Y; Matsuoka R; Amano T; Yamada T; Yabe I; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
    Cancer Sci; 2020 Oct; 111(10):3926-3937. PubMed ID: 32772458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project.
    Lee Y; Lee S; Sung JS; Chung HJ; Lim AR; Kim JW; Choi YJ; Park KH; Kim YH
    Cancer Res Treat; 2021 Jan; 53(1):123-130. PubMed ID: 32810930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bridging the Gap: Innovative 'Center for Precision Oncology' in Missouri.
    Gustafson B; Douglass L; Pluard T; Subramanian J
    Mo Med; 2023; 120(1):79-82. PubMed ID: 36860613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
    Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
    Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Universal Genomic Testing: The next step in oncological decision-making or a dead end street?
    Holch JW; Metzeler KH; Jung A; Riedmann K; Jost PJ; Weichert W; Kirchner T; Heinemann V; Westphalen CB
    Eur J Cancer; 2017 Sep; 82():72-79. PubMed ID: 28648701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach.
    Kato S; Kurasaki K; Ikeda S; Kurzrock R
    Oncologist; 2018 Feb; 23(2):171-178. PubMed ID: 29038235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physician interpretation of genomic test results and treatment selection.
    Brusco LL; Wathoo C; Mills Shaw KR; Holla VR; Bailey AM; Johnson AM; Khotskaya YB; Litzenburger BC; Sanchez NS; Zeng J; Bernstam EV; Eng C; Kee BK; Amaria RN; Routbort MJ; Mills GB; Mendelsohn J; Meric-Bernstam F
    Cancer; 2018 Mar; 124(5):966-972. PubMed ID: 29165790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomics-Enabled Precision Medicine for Cancer.
    Roos A; Byron SA
    Cancer Treat Res; 2019; 178():137-169. PubMed ID: 31209844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.
    Becerra MF; Reznik E; Redzematovic A; Tennenbaum DM; Kashan M; Ghanaat M; Casuscelli J; Manley B; Jonsson P; DiNatale RG; Blum KA; Durack JC; Solomon SB; Arcila ME; Bourque C; Socci N; Carlo MI; Lee CH; Voss MH; Feldman DR; Motzer RJ; Coleman JA; Russo P; Cheng EH; Hakimi AA; Hsieh JJ
    Eur Urol Focus; 2018 Dec; 4(6):986-994. PubMed ID: 29066084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. OpenGeneMed: a portable, flexible and customizable informatics hub for the coordination of next-generation sequencing studies in support of precision medicine trials.
    Palmisano A; Zhao Y; Li MC; Polley EC; Simon RM
    Brief Bioinform; 2017 Sep; 18(5):723-734. PubMed ID: 27422621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
    Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
    Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
    Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
    Tsimberidou AM
    Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.